Hospitalized Patient Data on SGLT-2 Inhibitors and Acute Kidney Injury Risk, 2021-2024

Supplementary data for a matched cohort study of 1,054 hospital admissions assessing the association between SGLT-2 inhibitor treatment and acute kidney injury risk. The dataset includes 527 admissions with and 527 without prehospital SGLT-2i use, with patient demographics, treatment indications, and clinical outcomes. The data was authored by figshare admin karger and last updated in April 2026.

Use Cases

• Assessing the association between SGLT-2 inhibitor use and acute kidney injury incidence based on matched cohort data.
• Analyzing the impact of continuing SGLT-2i treatment during hospitalization on clinical outcomes.
• Evaluating the relationship between acute kidney injury and length of hospital stay using the provided median and IQR values.
• Comparing mortality risk differences between patient groups with and without SGLT-2i treatment in the context of AKI.

Strengths

• Includes 1,054 hospital admissions with a 1:1 matched cohort design.
• Provides specific outcome metrics, including a 32% lower AKI risk (RR 0.68) for SGLT-2i users.
• Reports detailed patient demographics, such as a median age of 71 years and 34% women.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single medical center (Frisius Medical Centre Leeuwarden), which may limit generalizability.

Provenance

Source

figshare admin karger

Collection Method

Retrospective matched cohort study from hospital records.

Time Range

October 21, 2021, to February 12, 2024.

Freshness

Last updated 2026-04-15 11:55:15; freshness should be verified.

Geography

Frisius Medical Centre Leeuwarden (location not fully specified).